Case-control study examining MOTS-c and humanin gene expression in blood and plasma protein levels in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and cognitively normal controls, assessing whether MDP levels associate with AD markers and conversion from MCI to AD. Evaluates MDPs as neurodegeneration biomarkers. Provides clinical evidence for MOTS-c as a potential Alzheimer's disease biomarker—establishing whether mitochondrial peptide deficiency tracks AD progression and MCI conversion, with implications for early AD diagnosis and for understanding the mitochondrial contributions to neurodegeneration.
Rodríguez-Esparragón, Francisco; Cazorla-Rivero, Sara E; Torrealba, Eduardo; Cánovas-Molina, Ángeles; González-Hernández, Ayose N; Martín-Alfaro, Ruth; Afonso-Medina, María P; Martínez de Saavedra-Álvarez, María T; Pérez-Santana, Carmen G; Bartolomé, Carmen; Estupiñán, Lidia; González-Martín, Jesús M; Clavo, Bernardino